论文部分内容阅读
目的探讨利福昔明治疗腹泻型IBS的疗效。方法符合罗马Ⅲ诊断标准的46例IBS-D患者,随机分为两组,研究组给予利福昔明200mg,3次/d,共服药2周。对照组给予肠球菌、枯草杆菌二联活菌500mg,3次/d,服药2周,服药期间观察患者腹痛发生时间、次数,每日排便次数以及大便性状,排便时有无腹痛、腹胀等症状,同时观察患者服药后不良反应。结果两组治疗后单项症状计分和总症状计分均明显下降(P<0.05);治疗2周后总有效率分别为90.90%(20/22)和61.90%(14/21);不良反应少而且轻微。结论利福昔明可用于治疗IBS-D,疗效好且安全。
Objective To investigate the efficacy of rifaximin in treating diarrhea-type IBS. Methods Forty-six patients with IBS-D who met the diagnostic criteria of Rome Ⅲ were randomly divided into two groups. The study group was given rifaximin 200 mg three times daily for 2 weeks. Control group was given enterococci, Bacillus subtilis live together 500mg, 3 times / d, taking 2 weeks, during the observation of patients with abdominal pain occurred time and frequency of defecation times and stool traits, defecation, without abdominal pain, bloating and other symptoms , While observing the patient after taking adverse reactions. Results After treatment, the single symptom score and the total symptom score decreased significantly (P <0.05). After 2 weeks of treatment, the total effective rates were 90.90% (20/22) and 61.90% (14/21), respectively. Adverse reactions Less and less. Conclusion Rifaximin can be used to treat IBS-D, with good efficacy and safety.